Lavenne-Pardonge E - Search Results

1

Safety of low-molecular-weight heparin in pregnancy: a systematic review.

Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, Mac Gillavry MR, Hamulyák K, Theunissen IM, Hunt BJ, Büller HR. Sanson BJ, et al. Among authors: lavenne pardonge e. Thromb Haemost. 1999 May;81(5):668-72. Thromb Haemost. 1999. PMID: 10365733 Review.

2

The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants.

Moriau M, Lavenne-Pardonge E, Crasborn L, von Frenckell R, Col-Debeys C. Moriau M, et al. Among authors: lavenne pardonge e. Thromb Res. 1995 Jun 15;78(6):469-82. doi: 10.1016/0049-3848(95)00081-2. Thromb Res. 1995. PMID: 15714749 Clinical Trial.

3

Treatment of the Raynaud's phenomenon with piracetam.

Moriau M, Lavenne-Pardonge E, Crasborn L, von Frenckell R, Col-Debeys C. Moriau M, et al. Arzneimittelforschung. 1993 May;43(5):526-35. Arzneimittelforschung. 1993. PMID: 8328997

4

Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects.

Moriau M, Crasborn L, Lavenne-Pardonge E, von Frenckell R, Col-Debeys C. Moriau M, et al. Arzneimittelforschung. 1993 Feb;43(2):110-8. Arzneimittelforschung. 1993. PMID: 8457235 Clinical Trial.

5

Acquired activated protein C resistance in pregnancy.

Schlit AF, Col-De Beys C, Moriau M, Lavenne-Pardonge E. Schlit AF, et al. Among authors: lavenne pardonge e. Thromb Res. 1996 Nov 1;84(3):203-6. doi: 10.1016/0049-3848(96)00177-6. Thromb Res. 1996. PMID: 8914220 Clinical Trial.

6

Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction.

Col JJ, Col-De Beys CM, Renkin JP, Lavenne-Pardonge EM, Bachy JL, Moriau MH. Col JJ, et al. Am J Cardiol. 1989 May 15;63(17):1185-92. doi: 10.1016/0002-9149(89)90176-8. Am J Cardiol. 1989. PMID: 2653017

7

A novel preservation medium protecting prostacyclin production and endothelial integrity of the human saphenous vein graft.

Dion R, Lavenne-Pardonge E, Scheiff JM, Verhelst R, Baele P, Moriau M. Dion R, et al. Thromb Res Suppl. 1990;12:81-6. doi: 10.1016/0049-3848(90)90443-g. Thromb Res Suppl. 1990. PMID: 2082491

8

Case 5--1996. Thrombosis after the use of a heparin-coated cardiopulmonary bypass circuit in a patient with heparin-induced thrombocytopenia.

Van Dyck MJ, Lavenne-Pardonge E, Azerad MA, Matta AG, Moriau M, Comunale ME. Van Dyck MJ, et al. Among authors: lavenne pardonge e. J Cardiothorac Vasc Anesth. 1996 Oct;10(6):809-15. doi: 10.1016/S1053-0770(96)80211-4. J Cardiothorac Vasc Anesth. 1996. PMID: 8910165 No abstract available.

9

[Treatment of the first episode of pulmonary embolism in the hospital. Anticoagulants, anti-platelet aggregation drugs and thrombolysis stimulants].

Moriau M, Lavenne-Pardonge E, Col-De Beys C, Jaumin P, el Gariani A, Rubay J, Goenen M. Moriau M, et al. Acta Chir Belg. 1986 Mar-Apr;86(2):97-105. Acta Chir Belg. 1986. PMID: 3716728 French.

10

The lupus anticoagulant.

Moriau M, Lavenne-Pardonge E, Col-De Beys C, Lambert M, Coche E. Moriau M, et al. Ann Ital Med Int. 1986 Dec;1(4):303-6. Ann Ital Med Int. 1986. PMID: 3152786 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page